NAMS logo

NAMS Stock Overview

Profile

Full Name:

NewAmsterdam Pharma Company N.V.

Sector:

Healthcare

Industry:

Biotechnology

Country:

Netherlands

IPO:

February 9, 2021

Indexes:

Not included

Website:

http://www.newamsterdampharma.com

Description:

NAMS (NewAmsterdam Pharma Company NV) focuses on developing innovative therapies for cardiometabolic diseases. The company aims to address unmet medical needs through advanced research and clinical trials, targeting conditions like high cholesterol and fatty liver disease to improve patient outcomes and overall health.

Key Details

Price

$22.48

Market Cap

$2.47 B(Mid cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$45.56 M(+223.37% YoY)

Annual EPS

-$2.56(-19.07% YoY)

PE Ratio

-

Annual ROE

-46.20%

Annual Debt To Equity

0.00

Beta

0.82

Events Calendar

Earnings

Next earnings date:

May 9, 2025

Recent quarterly earnings:

Feb 26, 2025

Recent annual earnings:

Feb 26, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Feb 27, 25 Scotiabank
Sector Outperform
Feb 27, 25 Needham
Buy
Jan 28, 25 RBC Capital
Outperform
Jan 24, 25 RBC Capital
Outperform
Jan 14, 25 HC Wainwright & Co.
Buy
Dec 30, 24 HC Wainwright & Co.
Buy
Dec 11, 24 Scotiabank
Sector Outperform
Dec 5, 24 Needham
Buy
Nov 21, 24 Needham
Buy
Nov 11, 24 Needham
Buy

Screeners with NAMS included

Growing Shares Outstanding
Most recommended stocks
Stocks below analysts price target
Healthcare sector
All stocks
High Altman Z score stocks
Stocks above SMA 200
Biotechnology industry
Best performing stocks last 3 months
Mid cap stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$22.48
NAMS price is $22.48

Price All-time High

$27.36
NAMS price is currently -17.84% below its historical high of $27.36

Price Analysts Target

$45.34
NAMS price is currently -50.42% lower than the consensus analysts' forecast

Price Today Change

+4.46%
NAMS price is up +4.46% today

Price YTD Change

-12.53%
NAMS price is down -12.53% since January 1st

Price 3-Year Change

+129.62%
NAMS price is up +129.62% over the past 3 years

Market cap

Market Cap

$2.47 B
NAMS market capitalization is $2.47 billion

Market Cap 3-Year Change

-
NAMS market capitalization 3-year change is unknown

Market Cap All-time High

$2.84 B
NAMS market capitalization is currently -13.18% below its historical high of $2.84 billion

Market Cap Sector Rank

83.79%
NAMS market capitalization is higher than 83.79% of companies in Healthcare sector

Technical

Beta

0.82
NAMS beta is 0.82

200-day SMA

$19.77
NAMS price is currently +13.69% above its 200-day simple moving average

14-day RSI

55.41
NAMS 14-day relative strength index is 55.41

30-day Relative Volume

0.93
NAMS 30-day relative volume is 0.93

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$45.56 M
NAMS annual revenue is $45.56 million

Annual Revenue Analysts Estimate

$15.97 M
NAMS annual revenue is currently +185.34% higher than the consensus analysts' forecast

Annual Revenue 1-Year Change

+223.37%
NAMS annual revenue is up +223.37% year-on-year

Annual Revenue Sector Rank

46.42%
NAMS annual revenue is higher than 46.42% of companies in Healthcare sector

Profit

Annual Gross Profit

-
NAMS annual gross profit value is unknown

Annual Gross Margin

-
NAMS annual gross profit margin value is unknown

Annual Operating Profit

-$176.29 M
NAMS annual operating income is -$176.29 million

Annual Operating Margin

-386.91%
NAMS annual operating profit margin is -386.91%

Annual Net Income

-$241.60 M
NAMS annual net profit is -$241.60 million

Annual Net Margin

-530.25%
NAMS annual net profit margin is -530.25%

EPS

Annual EPS

-$2.56
NAMS annual earnings per share is -$2.56

Annual EPS Analysts Estimate

-$1.74
NAMS annual earnings per share is currently +47.04% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

-19.07%
NAMS annual earnings per share is down -19.07% year-on-year

Annual EPS Sector Rank

36.75%
NAMS annual earnings per share is higher than 36.75% of companies in Healthcare sector

ROA & ROE

Annual ROA

-39.88%
NAMS annual return on assets is -39.88%

Annual ROE

-46.20%
NAMS annual return on equity is -46.20%

EBIT & EBITDA

Annual EBIT

-$241.60 M
NAMS annual earnings before interest & taxes is -$241.60 million

Annual EBITDA

-$241.49 M
NAMS annual EBITDA is -$241.49 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
NAMS price to earnings ratio value is unknown

PE Ratio Sector Rank

-
NAMS price to earnings ratio is unknown

PB Ratio

PB Ratio

3.26
NAMS price to book ratio is 3.26

PB Ratio Sector Rank

72.36%
NAMS price to book ratio is higher than 72.36% of companies in Healthcare sector

PS Ratio

PS Ratio

54.18
NAMS price to sales ratio is 54.18

PS Ratio Sector Rank

92.08%
NAMS price to sales ratio is higher than 92.08% of companies in Healthcare sector

Enterprise value

Enterprise Value

$1.70 B
NAMS enterprise value is $1.70 billion

Enterprise Value Sector Rank

79.78%
NAMS enterprise value is higher than 79.78% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-7.03
NAMS EV/EBITDA is -7.03

EV/EBITDA Sector Rank

18.27%
NAMS EV/EBITDA is higher than 18.27% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

8.08
NAMS annual current ratio is 8.08

Annual Quick Ratio

-
NAMS annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.00
NAMS annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-
NAMS annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
NAMS piotroski f-score value is unknown

Altman Z-Score

13.10
NAMS altman z-score is 13.10

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$864.62 M
NAMS annual total assets is $864.62 million

Annual Non Current Assets

$1.21 M
NAMS annual long term assets is $1.21 million

Annual Current Assets

$863.41 M
NAMS annual total current assets is $863.41 million

Annual Cash & Cash Equivalents

$771.74 M
NAMS annual cash & cash equivalents is $771.74 million

Equity

Annual Book Value

$757.50 M
NAMS annual book value is $757.50 million

Annual Working Capital

$756.50 M
NAMS annual working capital is $756.50 million

Liabilities

Annual Total Liabilities

$107.12 M
NAMS annual total liabilities is $107.12 million

Annual Total Long Term Liabilities

$202.00 K
NAMS annual total long term liabilities is $202.00 thousand

Annual Current Liabilities

$106.92 M
NAMS annual total current liabilities is $106.92 million

Annual Accounts Payable

$4.74 M
NAMS annual accounts payable is $4.74 million

Debt

Annual Total Debt

$448.00 K
NAMS annual total debt is $448.00 thousand

Annual Total Debt 1-Year Change

+646.67%
NAMS annual total debt is up +646.67% year-on-year

Annual Long Term Debt

$202.00 K
NAMS annual long term debt is $202.00 thousand

Annual Short Term Debt

$246.00 K
NAMS annual short term debt is $246.00 thousand

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$221.85 M
NAMS annual total expenses is $221.85 million

Annual Operating Expenses

$221.85 M
NAMS annual total operating expenses is $221.85 million

Annual Cost Of Goods Sold

-
NAMS annual cost of goods sold value is unknown

Annual SGA

$70.45 M
NAMS annual SGA is $70.45 million

Annual D&A

$113.00 K
NAMS annual depreciation & amortization is $113.00 thousand

Annual Interest Expense

$0.00
NAMS annual interest expense is $0.00

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$158.56 M
NAMS annual cash flow from operations is -$158.56 million

Annual CFO 1-Year Change

-12.28%
NAMS annual cash flow from operations is down -12.28% year-on-year

Annual CFI

-$62.85 M
NAMS annual cash flow from investing activities is -$62.85 million

Annual CFI 1-Year Change

-261766.67%
NAMS annual cash flow from investing activities is down -261766.67% year-on-year

Annual CFF

$659.51 M
NAMS annual cash flow from financing activities is $659.51 million

Annual CFF 1-Year Change

+7300.21%
NAMS annual cash flow from financing activities is up +7300.21% year-on-year

Free CashFlow

Annual FCF

-$159.24 M
NAMS annual free cash flow is -$159.24 million

Annual FCF 1-Year Change

-12.74%
NAMS annual free cash flow is down -12.74% year-on-year

CAPEX

Annual CAPEX

$672.00 K
NAMS annual capital expenditures is $672.00 thousand

Annual CAPEX 1-Year Change

+2700%
NAMS annual capital expenditures is up +2700% year-on-year

Institutional Ownership

Similar stocks

TMDX logo
TransMedics (TMDX)
EWTX logo
Edgewise Therapeutics (EWTX)
PTGX logo
Protagonist Therapeutics (PTGX)
SEM logo
Select Medical Holdings (SEM)
TWST logo
Twist Bioscience (TWST)
LIVN logo
LivaNova (LIVN)
Rapport Therapeutics (RAPP)
BEAM logo
Beam Therapeutics (BEAM)
Ardent Health Partners LLC (ARDT)

FAQ

  • What is the ticker symbol for NewAmsterdam Pharma Company NV?
  • Does NewAmsterdam Pharma Company NV pay dividends?
  • What sector is NewAmsterdam Pharma Company NV in?
  • What industry is NewAmsterdam Pharma Company NV in?
  • What country is NewAmsterdam Pharma Company NV based in?
  • When did NewAmsterdam Pharma Company NV go public?
  • Is NewAmsterdam Pharma Company NV in the S&P 500?
  • Is NewAmsterdam Pharma Company NV in the NASDAQ 100?
  • Is NewAmsterdam Pharma Company NV in the Dow Jones?
  • When was NewAmsterdam Pharma Company NV's last earnings report?
  • When does NewAmsterdam Pharma Company NV report earnings?
  • Should I buy NewAmsterdam Pharma Company NV stock now?

What is the ticker symbol for NewAmsterdam Pharma Company NV?

The ticker symbol for NewAmsterdam Pharma Company NV is NASDAQ:NAMS

Does NewAmsterdam Pharma Company NV pay dividends?

No, NewAmsterdam Pharma Company NV does not pay dividends

What sector is NewAmsterdam Pharma Company NV in?

NewAmsterdam Pharma Company NV is in the Healthcare sector

What industry is NewAmsterdam Pharma Company NV in?

NewAmsterdam Pharma Company NV is in the Biotechnology industry

What country is NewAmsterdam Pharma Company NV based in?

NewAmsterdam Pharma Company NV is headquartered in Netherlands

When did NewAmsterdam Pharma Company NV go public?

NewAmsterdam Pharma Company NV's initial public offering (IPO) was on February 9, 2021

Is NewAmsterdam Pharma Company NV in the S&P 500?

No, NewAmsterdam Pharma Company NV is not included in the S&P 500 index

Is NewAmsterdam Pharma Company NV in the NASDAQ 100?

No, NewAmsterdam Pharma Company NV is not included in the NASDAQ 100 index

Is NewAmsterdam Pharma Company NV in the Dow Jones?

No, NewAmsterdam Pharma Company NV is not included in the Dow Jones index

When was NewAmsterdam Pharma Company NV's last earnings report?

NewAmsterdam Pharma Company NV's most recent earnings report was on Feb 26, 2025

When does NewAmsterdam Pharma Company NV report earnings?

The next expected earnings date for NewAmsterdam Pharma Company NV is May 9, 2025

Should I buy NewAmsterdam Pharma Company NV stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions